Up-regulation of NK Cell Activating Receptors Following Allogeneic Hematopoietic Stem Cell Transplantation under a Lymphodepleting Reduced Intensity Regimen is Associated with Elevated IL-15 Levels

Biology of Blood and Marrow Transplantation

Volumn 14, Issue 3, 2008, Pages 290-300

  Boyiadzis, Michael ^a,b   Memon, Sarfraz ^a   Carson, Jesse ^a   Allen, Kenton ^a   Szczepanski, Miroslaw J ^b   Vance, Barbara A ^a   Dean, Robert ^a   Bishop, Michael R ^a   Gress, Ronald E ^a   Hakim, Frances T ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

IL 15; Natural Cytotoxicity Receptors; Natural Killer Cells; NKG2D; Transplantation

Indexed keywords

CD56 ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; INTERLEUKIN 15; LYMPHOCYTE RECEPTOR; METHOTREXATE; NATURAL KILLER CELL RECEPTOR; NATURAL KILLER CELL RECEPTOR NKG2D; NATURAL KILLER CELL RECEPTOR NKP30; NATURAL KILLER CELL RECEPTOR NKP46; PREDNISONE; UNCLASSIFIED DRUG; VINCRISTINE;

ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIGEN EXPRESSION; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CYTOKINE RELEASE; DRUG DOSE REDUCTION; FEMALE; GRAFT VERSUS HOST REACTION; HODGKIN DISEASE; HUMAN; HUMAN CELL; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; MALE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NONHODGKIN LYMPHOMA; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; REDUCED INTENSITY CONDITIONING; T CELL DEPLETION; TUMOR CELL DESTRUCTION; TUMOR IMMUNITY;

ADULT; AGED; ANTIGENS, CD56; CELLS, CULTURED; FEMALE; GRAFT VS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INTERLEUKIN-15; KILLER CELLS, NATURAL; LYMPHOCYTE DEPLETION; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; MYELOFIBROSIS; RECEPTORS, IMMUNOLOGIC; TRANSPLANTATION, HOMOLOGOUS; UP-REGULATION;

EID: 38949100377     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2007.12.490     Document Type: Article

References (44)

1. Farag S.S., and Caligiuri M.A. Human natural killer cell development and biology. Blood Rev 20 (2006) 123-137
2. Garrido F., Ruiz-Cabello F., Cabrera T., et al. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today 18 (1997) 89-95
3. Rajagopalan S., and Long E.O. Viral evasion of NK-cell activation. Trends Immunol 26 (2005) 403-405
4. Carbone E., Neri P., Mesuraca M., et al. HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. Blood 105 (2005) 251-258
5. Le Maux Chansac B., Moretta A., Vergnon I., et al. NK cells infiltrating a MHC class I-deficient lung adenocarcinoma display impaired cytotoxic activity toward autologous tumor cells associated with altered NK cell-triggering receptors. J Immunol 175 (2005) 5790-5798
6. Pende D., Rivera P., Marcenaro S., et al. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res 62 (2002) 6178-6186
7. Moretta A., Bottino C., Vitale M., et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol 19 (2001) 197-223
8. Castriconi R., Cantoni C., Della Chiesa M., et al. Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. Proc Natl Acad Sci USA 100 (2003) 4120-4125
9. Dasgupta S., Bhattacharya-Chatterjee M., O'Malley Jr. B.W., et al. Inhibition of NK cell activity through TGF-beta 1 by down-regulation of NKG2D in a murine model of head and neck cancer. J Immunol 175 (2005) 5541-5550
10. Friese M.A., Wischhusen J., Wick W., et al. RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo. Cancer Res 64 (2004) 7596-7603
11. Lee J.C., Lee K.M., Kim D.W., et al. Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J Immunol 172 (2004) 7335-7340
12. Chklovskaia E., Nowbakht P., Nissen C., et al. Reconstitution of dendritic and natural killer-cell subsets after allogeneic stem cell transplantation: effects of endogenous flt3 ligand. Blood 103 (2004) 3860-3868
13. Jacobs R., Stoll M., Stratmann G., et al. CD16- CD56+ natural killer cells after bone marrow transplantation. Blood 79 (1992) 3239-3244
14. Nagler A., Rabinowitz R., Rosengolts-Rat J., et al. Natural killer (NK) and T cell-associated surface marker expression following allogeneic and autologous bone marrow transplantation (BMT). J Hematother Stem Cell Res 9 (2000) 63-75
15. Vitale C., Chiossone L., Morreale G., et al. Human natural killer cells undergoing in vivo differentiation after allogeneic bone marrow transplantation: analysis of the surface expression and function of activating NK receptors. Mol Immunol 42 (2005) 405-411
16. Petersen S.L., Ryder L.P., Bjork P., et al. A comparison of T-, B- and NK-cell reconstitution following conventional or nonmyeloablative conditioning and transplantation with bone marrow or peripheral blood stem cells from human leucocyte antigen identical sibling donors. Bone Marrow Transplant 32 (2003) 65-72
17. Jiang Y.Z., Barrett A.J., Goldman J.M., et al. Association of natural killer cell immune recovery with a graft-versus-leukemia effect independent of graft-versus-host disease following allogeneic bone marrow transplantation. Ann Hematol 74 (1997) 1-6
18. Cooley S., Xiao F., Pitt M., et al. A subpopulation of human peripheral blood NK cells that lacks inhibitory receptors for self-MHC is developmentally immature. Blood 110 (2007) 578-586
19. Grzywacz B., Kataria N., Sikora M., et al. Coordinated acquisition of inhibitory and activating receptors and functional properties by developing human natural killer cells. Blood 108 (2006) 3824-3833
20. Wang H., Grzywacz B., Sukovich D., et al. The unexpected effect of cyclosporin A on CD56+CD16- and CD56+CD16+ natural killer cell subpopulations. Blood 110 (2007) 1530-1539
21. Shilling H.G., McQueen K.L., Cheng N.W., et al. Reconstitution of NK cell receptor repertoire following HLA-matched hematopoietic cell transplantation. Blood 101 (2003) 3730-3740
22. Shilling H.G., Young N., Guethlein L.A., et al. Genetic control of human NK cell repertoire. J Immunol 169 (2002) 239-247
23. Ruggeri L., Capanni M., Tosti A., et al. Innate immunity against hematological malignancies. Cytotherapy 4 (2002) 343-346
24. Ruggeri L., Capanni M., Urbani E., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295 (2002) 2097-2100
25. Clausen J., Wolf D., Petzer A.L., et al. Impact of natural killer cell dose and donor killer-cell immunoglobulin-like receptor (KIR) genotype on outcome following human leucocyte antigen-identical haematopoietic stem cell transplantation. Clin Exp Immunol 148 (2007) 520-528
26. Bishop M.R., Steinberg S.M., Gress R.E., et al. Targeted pretransplant host lymphocyte depletion prior to T-cell depleted reduced-intensity allogeneic stem cell transplantation. Br J Haematol 126 (2004) 837-843
27. Dean R.M., Fowler D.H., Wilson W.H., et al. Efficacy of reduced-intensity allogeneic stem cell transplantation in chemotherapy-refractory non-hodgkin lymphoma. Biol Blood Marrow Transplant 11 (2005) 593-599
28. Friberg D.D., Bryant J.L., and Whiteside T.L. Measurements of Natural Killer (NK) Activity and NK-Cell Quantification. Methods 9 (1996) 316-326
29. Whiteside T.L., Bryant J., Day R., et al. Natural killer cytotoxicity in the diagnosis of immune dysfunction: criteria for a reproducible assay. J Clin Lab Anal 4 (1990) 102-114
30. Cooley S., McCullar V., Wangen R., et al. KIR reconstitution is altered by T cells in the graft and correlates with clinical outcomes after unrelated donor transplantation. Blood 106 (2005) 4370-4376
31. Chik K.W., Li K., Pong H., et al. Elevated serum interleukin-15 level in acute graft-versus-host disease after hematopoietic cell transplantation. J Pediatr Hematol Oncol 25 (2003) 960-964
32. Miller J.S., Soignier Y., Panoskaltsis-Mortari A., et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105 (2005) 3051-3057
33. Waldmann T.A. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol 6 (2006) 595-601
34. Fry T.J., Connick E., Falloon J., et al. A potential role for interleukin-7 in T-cell homeostasis. Blood 97 (2001) 2983-2990
35. Doherty T.M., Seder R.A., and Sher A. Induction and regulation of IL-15 expression in murine macrophages. J Immunol 156 (1996) 735-741
36. Neely G.G., Robbins S.M., Amankwah E.K., et al. Lipopolysaccharide-stimulated or granulocyte-macrophage colony-stimulating factor-stimulated monocytes rapidly express biologically active IL-15 on their cell surface independent of new protein synthesis. J Immunol 167 (2001) 5011-5017
37. Carson W.E., Fehniger T.A., Haldar S., et al. A potential role for interleukin-15 in the regulation of human natural killer cell survival. J Clin Invest 99 (1997) 937-943
38. Cooper M.A., Bush J.E., Fehniger T.A., et al. In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells. Blood 100 (2002) 3633-3638
39. Ranson T., Vosshenrich C.A., Corcuff E., et al. IL-15 is an essential mediator of peripheral NK-cell homeostasis. Blood 101 (2003) 4887-4893
40. Sivori S., Cantoni C., Parolini S., et al. IL-21 induces both rapid maturation of human CD34+ cell precursors towards NK cells and acquisition of surface killer Ig-like receptors. Eur J Immunol 33 (2003) 3439-3447
41. Sivori S., Falco M., Marcenaro E., et al. Early expression of triggering receptors and regulatory role of 2B4 in human natural killer cell precursors undergoing in vitro differentiation. Proc Natl Acad Sci USA 99 (2002) 4526-4531
42. Asai O., Longo D.L., Tian Z.G., et al. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation. J Clin Invest 101 (1998) 1835-1842
43. Savani B.N., Rezvani K., Mielke S., et al. Factors associated with early molecular remission after T cell-depleted allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood 107 (2006) 1688-1695
44. Ruggeri L., Capanni M., Casucci M., et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 94 (1999) 333-339